Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | TDO2 | P48775 | 3/20 | 0.52 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975957 | 1.00 | IDO1 (0.52) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL11640013 | 0.88 | TSHR (0.42) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL11488224 | 0.87 | TSHR (0.58) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL4815784 | 0.85 | TSHR (0.47) | IDO1TDO2IDO2ACP3TSHR | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL41575 | 0.76 | IDO1 (0.55) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL9677445 | 0.75 | TSHR (0.47) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL3392138 | 0.74 | IDO1 (0.52) | IDO1TDO2TSHRCYP2C19CYP2C9 | |
| SCHEMBL4014084 | 0.74 | IDO1 (0.53) | IDO1TDO2IDO2ACP3TSHR | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL29279416 | 0.74 | IDO1 (0.57) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL521541 | 0.74 | IDO1 (0.53) | IDO1TDO2IDO2ACP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333985-B1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240262814-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4333985-A1 | MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117561251-A | Modulators of TREX1 | 星座制药公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-105111148-A | 2-[(N-para-chlorophenyl)-3-pyrazole oxymethyl]nitrobenzene and preparation method therefor and application thereof | ANHUI COSTAR BIO CHEMICAL CO LTD | 2015-12-02 | — | — | CN | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262814-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | IDO1 4412/4885TDO2 4479/4885IDO2 4508/4885 |
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | IDO1 966/4885TDO2 1112/4885IDO2 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.